期刊文献+

关于福辛普利钠相关杂质的分析

Analysis on Relevant Impurities of Fosinopril Sodium
下载PDF
导出
摘要 文章对欧洲药典(EP7.0)、美国药典(USP34)和中国国家标准收录的13种福辛普利钠相关杂质归纳总结,并对相关杂质的生成原因进行追溯和解析。 In the thesis thirteen relevant impurities of Fosinopril which were recorded in European Pharmacopoeia(EP7.0), United States Pharmacopeia(USP34) and Chinese national standards were concluded and summarized. And the causing of relevant impurities were traced and analyzed.
出处 《广东化工》 CAS 2016年第12期115-117,共3页 Guangdong Chemical Industry
关键词 福辛普利钠 杂质 分析 fosinopril sodium impurities analysis
  • 相关文献

参考文献7

  • 1饶中和,袁志敏.福辛普利——第三代血管紧张素转换酶抑制剂[J].新医学,1996,27(9):486-487. 被引量:5
  • 2龚培力.抗高血压药物的评价与研究进展[J].医药导报,2007,26(4):334-339. 被引量:62
  • 3European Directorate for Quality Medicines. European Pharmacopoeia [S]. EP7.0:2073-2076. 被引量:1
  • 4The United States Pharmacopeial Convention. U.S. Pharmacopeia/National Formulary[S]. USP34/NF29: 2912-2915. 被引量:1
  • 5YBH05282006.国家食品药品监督管理周标准[S].北京:国家食品药品监督管理局,2005. 被引量:1
  • 6Krapcho J, Turk C, Cushman D W, et al. Angiotensin-Converting Enzyme Inhibitors. Mercaptan, Carboxyalkyl Dipeptide, and Phosphinic Acid lnhibitors Incorporating 4-Substituted Prolines[J]. J Med Chem, 1988,31 (6): 1148-1160. 被引量:1
  • 7Anderson N G, Ciarametla B M, Feldman A F, et al. Process Development tbr the Preparation of a Monopril Intermediate by a Trimethylsilyl-Modified Arbuzov Reaction[J]. Org Process Res DeV, 1997, 1: 211-216. 被引量:1

二级参考文献15

  • 1中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版)[M].北京:人民卫生出版社,2005. 被引量:117
  • 2CHOBANIAN A V,BAKRIS G L,BLACK H R,et al.The seventh report of the joint national committee on prevention,detection,evaluation and treatment of high blood pressure:the JNC-7 report[J].JAMA,2003,289(22):2560-2572. 被引量:1
  • 3Guidelines Committee.2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension[J].J Hypertens,2003,21:1021-1053. 被引量:1
  • 4ANON.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].JAMA,2002,288(23):2981 -2997. 被引量:1
  • 5JOUNELA A J,LILJA M,LUMMEJ,et al.Relation between low dose of hydrochlorothiazide,antihypertensive effect and adverse effects[J].Blood Press,1994,3:231-235. 被引量:1
  • 6POOLE-WILSON PA,LABSEN J,KIRWAN B A,et al.Effect of long acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial):randomized controlled trial[J].Lancet,2004,364 (9437):849 -857. 被引量:1
  • 7WING L M,REID C M,RYAN P,et al.A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly[J].N Engl J Med,2003,348(7):583 -592. 被引量:1
  • 8JULIUS S,KJELDSEN S E,WEBER M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].Lancet,2004,363:2022 -2031. 被引量:1
  • 9KOSTIS J B,PACKER M,BLACK H R,et al.Omapatrilat and enalapril in patients with hypertension:the Omapatrilat Cardiovascular Treatment vs.Enalapril (OCTAVE) trial[J].Am J Hypertens,2004,17 (2):103-111. 被引量:1
  • 10WILLIAMS G H,BURGESS E,KOLLOCH R E,et al.Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension[J].Am J Cardiol,2004,93 (8):990-996. 被引量:1

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部